Loading
NASDAQHealthcareBiotechnology
Latest quote
$9.40
+$0.12 · +1.29%
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Previous close
$9.40
+$0.12 · +1.29%
After-hours
$9.37
−$0.03 · -0.32%
Sep 4, 7:51 PM ET
Regular session · ET · Market data may be delayed.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Day range
Current $9.40
52-week range
Current $9.40
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
30
Expensive
Sentiment
69
Bullish
Risk
59
Elevated Risk
Momentum
36
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Day range
Current $9.40
52-week range
Current $9.40
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$10.63
13.09% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 5, 2019 | 1:10 | — | — |
Stock split | Nov 21, 2013 | 1:50 | — | — |
Stock split | Feb 13, 2007 | 1:10 | — | — |
Effective Jun 5, 2019
1:10
Effective Nov 21, 2013
1:50
Effective Feb 13, 2007
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI21.49M0.19%11.49B USD0.35%$163.81-0.35%
iShares Russell 2000 ETFIWM13.8M0.02%79.88B USD0.19%$296.01+0.28%
Vanguard Morningstar Total Stock Market ETFVTI6.37M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 Growth ETFIWO4.94M0.03%14.58B USD0.24%$377.54+0.12%
Vanguard Extended Market ETFVXF2.28M0.00%93.7B USD0.05%$242.66+0.14%
Vanguard U.S. Momentum Factor ETFVFMO2.05M0.10%1.8B USD0.13%$229.8+0.93%
Vanguard Russell 2000 ETFVTWO1.16M0.01%17.4B USD0.06%$119.62+0.25%
Federated Hermes MDT Small Cap Core ETFFSCC719.89K0.17%360.9M USD0.50%$35.71+0.27%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard U.S. Momentum Factor ETFVFMOVanguard Russell 2000 ETFVTWOFederated Hermes MDT Small Cap Core ETFFSCCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
